Clinical trials
Gram Negative Infections clinical trials
Below are recruiting gram negative infections clinical trials, each written for real people, not researchers. We’re tracking 24 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07749508Recruiting
Study on gram-negative bacterial infections
This study looks at infections caused by gram-negative bacteria (a type of bacteria that can cause serious illness). It aims to learn more about these infections and how to treat them, which might help improve care for patients with such infections.
Madrid, MadridAges Any age - NCT06717594Recruiting
Study of antibiotics for resistant infections
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
Bologna, BolognaAges 18 years+ - NCT06651047Recruiting
Study of antibiotics for difficult Gram-negative infections
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
BolognaAges Any age - NCT06537609Recruiting
Testing treatments for Gram-negative bloodstream infections
This trial tests different ways to treat infections in the blood caused by Gram-negative bacteria. It looks at whether reducing antibiotics, switching to pills, or managing central lines improves outcomes while keeping you safe.
Kogarah, New South WalesAges birth–130 years - NCT06828848RecruitingPhase 2
Study of Vaborem in children with Gram negative infections
This trial tests how Vaborem is absorbed and tolerated in children with serious bacterial infections, including complicated urinary tract infections. It aims to find the right dose for children.
OstravaAges birth–17 years - NCT07372131Recruiting
Shorter antibiotics for high-risk fever with low white blood cells
This study looks at how long antibiotics should be given to cancer patients with fever and very low white blood cell counts after finding a certain type of bacteria (Gram-negative) in their blood. The goal is to find the best treatment duration to help patients recover without complications.
Rozzano, MilanAges 18 years+ - NCT04291768RecruitingPhase 4
Shorter 5-day antibiotics for certain gram-negative bloodstream infections
This trial tests whether people with a specific type of bloodstream infection caused by gram-negative bacteria can safely take antibiotics for only 5 days instead of longer. It may help by reducing antibiotic exposure if your infection source is controlled quickly.
AalborgAges 18 years+ - NCT06080698Recruiting
Oral antibiotics for bloodstream infection trial
This trial tests whether switching from IV to oral antibiotics is just as effective for treating Gram-negative bloodstream infections. If you qualify, you may receive either continued IV antibiotics or switch to pills, with follow-up on your recovery and quality of life.
San Francisco, CaliforniaAges 18 years+ - NCT06135350RecruitingPhase 2
Preventing infections in ICU patients on ventilators
This trial tests an experimental drug called Fluorothiazinone to prevent serious bacterial infections in ICU patients who are on a breathing machine (ventilator) or likely to need one soon. It includes patients with COVID-19 pneumonia, stroke, or heart failure.
Moscow, MoscowAges 18 years+ - NCT06462235RecruitingPhase 2
Testing a new antibiotic for hospitalized babies with infection
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
Orange, CaliforniaAges Up to 9 months - NCT07206745Recruiting
Chinese and Western medicine for severe pneumonia from drug-resistant bacteria
This trial tests a combination of traditional Chinese and Western medicine for adults with severe pneumonia caused by bacteria that are resistant to multiple antibiotics. It aims to see if this combined approach can improve treatment outcomes.
Zhengzhou, HenanAges 18–80 - NCT06966284Recruiting
Study Comparing Two Antibiotics for Resistant Infections
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
TaipeiAges 18 years+ - NCT07004049RecruitingPhase 4
Testing combinations for resistant Gram-negative infections
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Brisbane, QueenslandAges 18 years+ - NCT07063095RecruitingPhase 3
Testing two antibiotics combined for serious bacterial infections
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Geneva, Canton of GenevaAges 18 years+ - NCT05639647RecruitingPhase 2
Aztreonam plus avibactam for serious gram-negative infections
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
San Diego, CaliforniaAges 9 months–17 years - NCT07491419Recruiting
Test to Speed Up Antibiotic Choice for Blood Infections
This trial checks if a faster test to find the best antibiotic for a bloodstream infection can improve treatment and outcomes. If you have a confirmed bloodstream infection, you may be able to join.
Rozzano, MilanAges 18 years+ - NCT06907069Enrolling by invitationPhase 4
Combined treatment for drug-resistant bacteria in lung infections
This trial tests if giving a medication (colistin) both through an IV and as a mist you breathe in works better for lung infections caused by bacteria that are hard to treat with standard antibiotics. It may help patients who have these tough bacteria and are in the hospital.
Ningbo, ZAges 18–80 - NCT07176247Enrolling by invitation
Study of aztreonam-avibactam for drug-resistant infections
This trial studies a combination antibiotic called aztreonam-avibactam for treating infections caused by hard-to-treat bacteria, especially those that produce certain enzymes (MBLs). It aims to see how well this medicine works in hospital patients.
ParisAges Any age - NCT06595979Recruiting
Testing antibiotics through a brain drain for hard-to-treat infections
This trial is for adults with a serious brain infection caused by drug-resistant bacteria. It tests giving an antibiotic (polymyxin B) directly into the brain through a drain tube to see if it works better.
Hangzhou, ZhejiangAges 18–75 - NCT06843668RecruitingPhase 2/Phase 3
Best ways to give colistin for tough infections in the ICU
This study tests different ways of giving the antibiotic colistin to patients in the ICU with infections that are hard to treat. The goal is to find the best dosing schedule to help you fight the infection more effectively.
BuraidahAges 18 years+ - NCT07478484RecruitingPhase 4
Different ways to take antibiotics for resistant infections
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
Nanjin, JiangsuAges 18–100 - NCT07086391Recruiting
Inhaled Polymyxin B for Resistant Pneumonia
This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.
Fuzhou, FujianAges 18–90 - NCT05565222RecruitingPhase 3
Testing two antibiotics as alternatives for ICU severe ESBL infections
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
ParisAges 18 years+ - NCT06602557RecruitingPhase 2
Inhaled antibiotic for lung infection during ECMO support
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
ParisAges 18 years+
Hear when a new Gram Negative Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gram negative infections?
- Yes. Clin2 currently lists 24 recruiting gram negative infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gram negative infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gram negative infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.